The role of adjuvant external beam radiation therapy for papillary thyroid carcinoma invading the trachea.
- Author:
Young Suk KIM
1
;
Jae Hyuck CHOI
;
Kwang Sik KIM
;
Gil Chae LIM
;
Jeong Hong KIM
;
Ju Wan KANG
;
Hee Sung SONG
;
Sang Ah LEE
;
Chang Lim HYUN
;
Yunseon CHOI
;
Gwi Eon KIM
Author Information
- Publication Type:Original Article
- Keywords: Thyroid carcinoma; Papillary; Radiotherapy; Adjuvant; Trachea
- MeSH: Esophagus; Follow-Up Studies; Humans; Incidence; Iodine; Neoplasm Metastasis; Radiotherapy; Recurrence; Survival Rate; Thyroid Gland*; Thyroid Neoplasms*; Trachea*; Xerostomia
- From:Radiation Oncology Journal 2017;35(2):112-120
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To evaluate the effect of adjuvant external beam radiation therapy (EBRT) on local failure-free survival rate (LFFS) for papillary thyroid cancer (PTC) invading the trachea. MATERIALS AND METHODS: Fifty-six patients with locally advanced PTC invading the trachea were treated with surgical resection. After surgery, 21 patients received adjuvant EBRT and radioactive iodine therapy (EBRT group) and 35 patients were treated with radioactive iodine therapy (control group). RESULTS: The age range was 26–87 years (median, 56 years). The median follow-up period was 43 months (range, 4 to 145 months). EBRT doses ranged from 50.4 to 66 Gy (median, 60 Gy). Esophagus invasion and gross residual disease was more frequent in the EBRT group. In the control group, local recurrence developed in 9 (9/35, 26%) and new distant metastasis in 2 (2/35, 6%) patients, occurring 4 to 68 months (median, 37 months) and 53 to 68 months (median, 60 months) after surgery, respectively. Two patients had simultaneous local recurrence and new distant metastasis. There was one local failure in the EBRT group at 18 months after surgery (1/21, 5%). The 5-year LFFS was 95% in the EBRT group and 63% in the control group (p = 0.103). In the EBRT group, one late grade 2 xerostomia was developed. CONCLUSION: Although, EBRT group had a higher incidence of esophagus invasion and gross residual disease, EBRT group showed a better 5-year LFFS. Adjuvant EBRT may have contributed to the better LFFS in these patients.
